Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

pNGVL4a-Sig/E7(detox)/HSP70 DNA and HPV16 L2/E6/E7 fusion protein TA-CIN vaccine PVX-2

A cancer vaccine consisting of a combination of two vaccines, a prime pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine and a boost HPV16 L2/E6/E7 fusion protein TA-CIN vaccine, with potential immunostimulating and antineoplastic activities. pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine is an antigen-specific DNA cancer vaccine consisting of the coding sequences of a signal peptide (pNGVL4a-Sig), a detox form of the human papillomavirus type 16 (HPV-16) antigen E7, and the heat shock protein 70 (HSP70). Upon administration, this prime vaccine may generate potent cytotoxic CD8(+) T-cell responses against E7-expressing tumor cells, resulting in tumor cell death. HPV16 L2/E6/E7 fusion protein TA-CIN vaccine is a recombinant human papillomavirus (HPV), genetically engineered fusion protein vaccine in which the three HPV16 viral proteins L2, E6 and E7 are fused together in a single tandem fusion protein (TA-CIN; HPV16 L2\E6\E7). Upon administration, this boost vaccine may stimulate the immune system to generate HPV16 E6\E7-specific CD4+ and CD8+ T-cell responses as well as the induction of L2-specific antibodies. In addition, this vaccine may prevent infection and the development of other HPV16-associated diseases. L2, a minor viral capsid protein, is able to induce a strong antibody response against certain HPV types.
Code name:PVX 2
PVX-2
PVX2
Search NCI's Drug Dictionary